Data from Clinicaltrials.gov - Curated by Toby Galbraith - Last updated 27 September 2017

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

purpose

The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multiple Cardiac Sensors for the Management of Heart Failure
Estimated Enrollment: 2700
Anticipated Study Start Date: September 2017
Estimated Study Completion Date: January 2025
Estimated Primary Completion Date: October 2024 (Final data collection date for primary outcome measure)

Arms:
- Active Comparator:
HeartLogic ON
- Placebo Comparator: HeartLogic OFF

Category Value
Date last updated at source 03-Aug-17
Study type(s) Interventional
Expected enrolment 2700
Study start date 01-Sep-17
Estimated primary completion date 01-Oct-24

View full details

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation

Related Content